MedTrace Logo

Assessment of Continuous Positive Airway Pressure Therapy in OSA and ILD

NCT03901534 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2021

Last updated 2024-12-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate whether biomarkers of lung epithelial and endothelial injury are associated with obstructive sleep apnea (OSA) and interstitial lung disease (ILD).

Conditions

Interventions

DEVICE

Continuous positive airway pressure (CPAP) therapy

Standard, clinically used CPAP therapy. CPAP will be prescribed by the participants' clinician provider and not by the study investigators.

DEVICE

Nox A1 Recorder

Non-invasive, body-worn, sleep recording device for nocturnal polysomnography.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Columbia University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-10-16
Completion
2023-10-16
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03901534 on ClinicalTrials.gov